Self-Injection Pens for Chronic Therapies: RA, Psoriasis, Crohn's and MS Programs
Published 2026-10-28 · Keywords: rheumatoid arthritis injector
Chronic immune-therapy programs — rheumatoid arthritis, psoriasis, Crohn’s disease, multiple sclerosis — share one device reality: the same user injects the same device for years, often with reduced hand dexterity caused by the very disease being treated. A rheumatoid arthritis injector must therefore be judged on a longer and harder usability curve than any acute-use device.
What years of self-injection demand
| Chronic-therapy reality | Device requirement | Design answer |
|---|---|---|
| Reduced grip strength (RA) | Low activation force, ergonomic body | Spring-driven platforms with verified trigger force |
| Long-term repeated use | Reusable option with cartridge replacement | WH-RG (5 mL cartridge), A-60 (1–60 IU) |
| Therapy adherence economics | Fewer SKUs across titration | Adjustable platforms covering the full schedule |
| Home storage and travel | Robust housing, simple workflow | Two-step activation with defined click feedback |
| Dose stability between visits | Consistent delivery across cartridge batches | Compatibility verified per cartridge supplier |
Reusable or disposable for a chronic biologic?
The economics and the user profile point the same way for most chronic programs: a reusable pen amortizes one mechanism across years of injections, and the cartridge-change workflow becomes routine by week two. Disposable wins where cold-chain turnover, travel convenience or single-course treatment dominates. The 5-year cost model is arithmetic once your annual dose count is known — we run both quotations on the same basis so the crossover is visible in one table.
The human-factors evidence RA teams should expect
Device-side inputs that feed your validation: measured activation force, dose-step feedback behaviour, end-of-dose signal specification, and the cartridge-change sequence. A supplier who hands these over as tested facts shrinks your validation study; one who sends adjectives expands it.
What this does not cover
The devices ship empty and contain no drug — naming immune therapies here describes the user profile, not a claim. Dosing, titration and clinical decisions are your team’s.
Next step: send your annual dose count per patient and target markets — we return both cost quotations and the usability evidence set within one working day. Start the inquiry.
Related reading
Talk to NOVIXPEN about your program
Send your container format, annual volume and target market — we reply with the platform match, documentation set and written quotation within one working day.
Start the inquiry